TANGO THERAPEUTICS INC
TNGXNASDAQ🏆 #1050 by market capUS Equity
$26.32▼ $1.29 (−4.91%)
Live1h—
24h▼ 4.9%
7d▼ 10.5%
14d▼ 1.3%
30d▼ 15.3%
1y▲ 310.3%
🏦Market Cap
$4.27B
Small Cap
📈Revenue Growth (YoY)
+39.0%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
67.7x
Expensive
Otter Score
52
Weak
Trading Snapshot
- Day Range
- $25.93 – $26.79
- 52-Week Range
- $6.25 – $34.39
- Volume
- $3.92B
- Avg Volume
- $3.94B
- Shares Outstanding
- 162.3M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $67M
- Last Q Revenue
- $16M
- P/E Ratio
- —
- P/S Ratio
- 67.7x
- EPS (TTM)
- $-0.83
- Dividend Yield
- —
Why Investors Own TNGX
- ✓High-growth profile — revenue up +46.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$67M▲ +49.8% YoY
Gross Margin (TTM)
58.3%▲ +1.3% YoY
Operating Income (TTM)
$22M▲ +49.8% YoY
Free Cash Flow (TTM)
$5M▲ +49.8% YoY
About TANGO THERAPEUTICS INC
A company profile for TANGO THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
52/100
Analyst Price Target
ⓘAverage Target
$26.63
▲ +1.2% Upside
High Target$32.71
Low Target$24.93
Based on 27 analysts
Latest News & Updates
🚀
Reuters·2h ago
TANGO THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift TNGX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
TANGO THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.